Holds one active US DMF and 2 valid CEPs for felodipine, filing since 2011. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 18 markets.
Holds one active US DMF and 4 valid CEPs for felodipine, filing since 1995. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 34 markets.
Holds one active US DMF for felodipine, filing since 1999. Its 2023 FDA inspection closed as VAI, and its GMP is recognised in 7 markets.
Holds 2 valid CEPs for felodipine, filing since 2025. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 19 markets.
Holds one active US DMF and one valid CEP for felodipine, filing since 2003.
Holds one active US DMF and one valid CEP for felodipine, filing since 2007. Its 2025 FDA inspection closed as VAI.
Holds one active US DMF for felodipine, filing since 2008.
Holds one active US DMF for felodipine, filing since 2006. Its 2025 FDA inspection closed as VAI.
Holds 2 active US DMFs for felodipine, filing since 2026.
The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.
Contract manufacturers make to order rather than holding their own filing for this molecule.
The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Every factor appears on the card it produced. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for free